Corona Remedies Limited has filed its quarterly regulatory certificate with stock exchanges for the fourth quarter ended March 31, 2026. The pharmaceutical company submitted the mandatory documentation to both BSE Limited and National Stock Exchange of India Limited on April 07, 2026, as part of its ongoing compliance obligations.

Regulatory Certificate Details

The certificate was filed pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. Company Secretary and Compliance Officer Chetna Dharajiya signed the submission letter, which was accompanied by the required certificate from the company's registrar.

Certificate Confirmation

Bigshare Services Private Limited, serving as the company's Registrar to Issue and Share Transfer Agent, issued the certificate dated March 31, 2026. The registrar confirmed that Regulation 74(5) is not applicable to Corona Remedies Limited during the specified quarter.

The key findings include:

• All company shares remain in demat form
• No requests received for rematerialisation during the quarter
• No requests received for dematerialisation during the quarter
• Full compliance with depositories regulations maintained

Compliance Framework

The filing demonstrates Corona Remedies' adherence to SEBI's regulatory framework for listed companies. The certificate was simultaneously submitted to both National Securities Depository Limited and Central Depository Services (India) Limited, ensuring comprehensive regulatory coverage.

Company Information

Corona Remedies Limited, formerly known as Corona Remedies Private Limited, operates from its registered office at Corona House in Ahmedabad, Gujarat. The company maintains its listing on both major Indian stock exchanges and continues to fulfill all mandatory disclosure requirements under securities regulations.

Corona Remedies has reported a strong operating cash flow to EBITDA ratio of around 87%, highlighting the company's robust cash generation capabilities and financial health.

Strong Cash Flow Performance

The pharmaceutical company's operating cash flow to EBITDA ratio of approximately 87% demonstrates its ability to convert earnings into actual cash flow effectively. This metric is particularly significant as it indicates the company's operational efficiency and cash management capabilities.

Strategic Growth Opportunities

Corona Remedies emphasized that this strong cash flow position provides the company with substantial room for further acquisitions. The robust financial metrics indicate that the company is well-positioned to pursue strategic expansion opportunities and strengthen its market presence through targeted acquisitions.

The company's strong cash generation capability suggests it has the financial flexibility to explore growth opportunities while maintaining operational stability. This financial strength positions Corona Remedies favorably for executing its expansion strategy in the pharmaceutical sector.